AusBiotech 2025: Company Directory

Argenica Therapeutics (ASX: AGN) is a Perth-based, clinical-stage biotechnology company developing first-in-class neuroprotective drugs to reduce brain injury after stroke and other acute brain injuries. Its lead candidate, ARG-007, is a synthetic peptide designed to protect vulnerable brain cells and enhance patient outcomes when administered alongside standard care in acute ischaemic stroke. Beyond stroke, Argenica is exploring applications in traumatic brain injury and hypoxic-ischaemic encephalopathy, with the goal of delivering transformative treatments for patients with urgent neurological needs.

Learn more on the Argenica website.

BlinkLab is an ASX listed digital healthcare company founded by neuroscientists at Princeton University that has over the past several years developed a smartphone based diagnostic platform for autism, ADHD, and other neuropsychiatric conditions.

BlinkLab’s most advanced product is an autism diagnostic test that leverages the power of smartphones, neuroscience and AI to deliver screening tests specifically designed for young children. This marks a significant advancement, considering traditional diagnoses typically occur around five years of age, often missing the crucial early window for effective intervention.

BlinkLab is led by an experienced management team and directors with a proven track record in building companies and vast knowledge in neuroscience, digital healthcare, computer vision, AI and machine learning. Our Scientific Advisory Board consists of leading experts in the field of autism and brain development allowing us to bridge the most advanced technological innovations with groundbreaking scientific research.

Learn more on the BlinkLab website.

We are GMP TGA certified radiopharmaceutical manufacturer who provides radiopharmaceutical solutions to the local markets we serve.

We are a state of the art facility able to manufacture short and long lived cyclotron produced PET radiopharmaceuticals such as: Fluorine 18 labelled as well as copper 64, zirconium 89 and gallium 68 labelled products.

We work with universities, startups, biotechnology and established pharmaceutical companies in the manufacture of radiopharmaceuticals for human trials as well as commercial manufacture and distribution of established and approved agents.

Learn more on the Cyclowest website.  

Western Australia is fast becoming a global hub for health and medical life sciences with our proximity to the growing ASEAN market and strong health leadership.  Our health and medical life sciences industry has more than doubled in the five years from 2017 to 2022.  Western Australia's collaborative and vibrant ecosystem includes more than 100 medtech, digital health and biotech companies, 21 research institutes and foundations, 5 universities and 6 tertiary hospitals.

The Western Australian Government is committed to the State’s burgeoning life sciences sector.  In October 2021 we launched the State’s first-ever Health and Medical Life Sciences Industry Strategy, with $8.65 million being invested to implement the strategy.  

Learn more on the Invest and Trade Western Australia: Health and Medical Life Sciences website.

The Department of Health provides leadership and management of the WA public health system to ensure the delivery of safe and timely health services.  

The Office of Medical Research and Innovation provides policy and funding support for health and medical research and innovation and supports the Future Health Research and Innovation Fund's operations.

The future is bright for health and medical research and innovation in Western Australia.

Learn more on the Department of Health website.

Epichem is a leading synthetic and medicinal chemistry contract research organisation (CRO) with over 20 years of experience supporting a global client base. Established in 2003, we operate from a purpose-built, state-of-the-art laboratory in Perth, Western Australia.

We provide synthetic, medicinal and analytical chemistry services to the pharmaceutical, agrochemical and other chemistry-dependant industries. With extensive expertise in medicinal chemistry, we accelerate drug discovery and development  with expertise across oncology, senolytics, antivirals, cardiovascular and infectious diseases. Acting as an extension of our clients’ teams, we deliver practical, commercially minded chemistry solutions.

Epichem’s award-winning PhD-qualified scientists operate under strict controls to protect client intellectual property, which remains fully owned by the client within Australia’s robust IP and legal framework. All chemistry is performed in-house in Australia, with no hidden outsourcing.  Partner with Epichem to accelerate your discovery with world-class chemistry expertise.

Learn more on the Epichem website.

Championing innovation, collaboration, and commercialisation across Western Australia’s life sciences sector.

We connect people, ideas, and opportunities.  Showcasing WA innovation, attracting investment, and driving global impact.

Driving our sector forward, together.

Learn more on the LSWA website

Founded in 2010 by the Harry Perkins Institute of Medical Research, Linear is a leading for-purpose clinical trials organisation with a team of more than 250 dedicated staff. Since inception, we have delivered over 500 studies, with more than 75% being true first-in-human trials, demonstrating our expertise at the forefront of medical innovation.

We support all phases of clinical research across three state-of-the-art clinics, each designed to provide excellence in participant care and trial delivery. With fast-track approval pathways through private ethics, we are uniquely positioned to accelerate the progress of new treatments.

Linear was the first site in Australia to pioneer and adopt eSource technology, reinforcing our commitment to innovation, quality, and efficiency. As an accredited private hospital, we offer the highest standards of safety and compliance for participants and sponsors alike.

Our success has been recognised nationally, with multiple wins at the Australian Export Awards. This achievement reflects both the global impact of our work and our enduring purpose: To advance human health through greater access to innovative medical therapies.

Learn more on the Linear Clinical Research website.

Since 2010, Orthocell has been developing, manufacturing and exporting innovative regenerative medicine products.

To date, more than 70,000 patients have benefited from an Orthocell collagen medical device, with no reported adverse events as of March 2025.

Every product reflects our mission: improving mobility, function, and quality of life.¹ We collaborate with leading surgeons and centres of excellence to translate research into practical solutions that raise the standard of care.

Our deep understanding of tissue engineering, particularly the interaction between cells and scaffolds, allows us to enhance the body’s natural healing and regeneration of nerve, tendon, cartilage and bone.

Orthocell products are designed to simplify procedures, save operative time, and deliver consistent, predictable outcomes, supporting surgeons in providing the best care for their patients.

Learn more on the Orthocell website.

Perron Institute: Leaders in innovative neuroscience research and patient care

One in three people globally live with a neurological condition. Many of these conditions have no effective treatment and we are working to create a future of personalised, precision medicine by tackling these areas of unmet need. We operate statewide specialist neurological services and connect clinicians, researchers, industry and communities to develop new methods of diagnosis, treatment, and prevention, improving the lives of people with neurological conditions. 

Learn more on the Perron Institute website.

Proteomics International is a pioneering medical technology company operating at the forefront of predictive diagnostics and bio-analytical services. We specialise in proteomics – the large-scale study of protein structure and function.

Our ISO 17025-accredited laboratory delivers validated analytical results, serving global pharma, biotech and academic partners.

Registered as a Research Services Provider (RSP) (RSP000020), enabling eligible clients to claim tax incentives.

Expertise:

• Pharmacokinetic (PK) Services
• Biosimilars/Biologics Drug Characterisation
• Biomarker Discovery & Validation
• Specialist Protein Testing

Learn more on the Proteomics website.

Reliis is a Western Australian-based clinical-stage pharmaceutical company developing innovative medicines with significant commercial value that address critical unmet medical needs. Our strategy leverages recent clinical insights and a dynamic, model-informed drug development approach to accelerate novel therapies to market.

Our lead asset, RLS-2201, is a proprietary injectable formulation of the established atypical antipsychotic quetiapine. RLS-2201 targets the urgent unmet need for effective delirium treatment, offering easy administration, rapid action, and consistent therapeutic effects. This translates to superior patient outcomes by minimizing cognitive decline potential, enhancing safety, and improving clinical utility.  Our development strategy capitalises on the established safety and efficacy data of the original oral therapy, significantly reducing the time, cost, and risk for RLS-2201. We employ a data-driven platform that continuously refines dosing models throughout clinical trials, allowing us to move beyond standard clinical trial strategies toward more quickly maximising patient outcomes.

With a unique value proposition and a compressed development timeline, we offer investors and partners exceptional exposure to therapies with high unmet need, proven pharmacological validation, and strong potential for regulatory and commercial success.

Learn more on the Reliis website.

Resonance Health is an Australian healthcare technology and services ASX-listed company, headquartered in Perth, WA. The Company delivers innovative medical imaging solutions and clinical trial services to support the diagnosis, management and treatment of human diseases.

Resonance Health operates through three specialised divisions:

Resonance Health Analysis Services
RHAS provides regulatory-approved medical imaging analysis services, underpinned by scientific rigour and commitment to quality. The division has secured regulatory clearances for several medical devices in the United States (FDA), Europe (CE Mark), the United Kingdom, and Australia. 
Key offerings include: 
• FerriScan® –glob al gold standard to non-invasively quantify liver iron 
• HepaFatScan® – MRI-based solution for assessment of liver fat. 
Currently developing a novel, MRI-based diagnostic tool to non-invasively assess and monitor liver fibrosis.

Resonance Clinical 
Resonance Clinical is a boutique CRO that partners with pharmaceutical and biotech companies to conduct and manage clinical trials in Australia.

TrialsWest 
TrialsWest is a network of Investigator Sites strategically located across Western Australia dedicated clinical trial site management organisation coordinating participant recruitment and site operations across a range of therapeutic areas.

Together, Resonance Health's three divisions offer comprehensive, end-to-end clinical trial solutions in Australia—from central imaging and diagnostics to full-service CRO support and site operations. This integrated model ensures streamlined delivery, regulatory efficiency, and high-quality outcomes for local and global partners.
 

Learn more on the Resonance Health website.

RNA manufacturing facility dedicated to delivering high-quality mRNA and formulations for scientific discovery and inspiring innovative mRNA solutions.

Our vision is to become a premier RNA R&D facility and training ground that drives innovation for transformative global solutions.

• End-to-end capabilities of mRNA manufacturing supporting preclinical research (TRL 1-4)
• Supporting mRNA projects for any application
• RNA Design: design and development of mRNA to influence stability and longevity using synthetic biology, computational methods and AI
• High-throughput small and medium-scale mRNA and DNA template production and analysis
• Lipid nanoparticle (LNP) formulations and analytics
• Quality assurance equivalent to industry standards
• Catalogue mRNAs, such as reporter mRNAs
• Competitive tiered pricing (part of Therapeutics Innovation Australia)

Learn more on the RNA Innovation Foundry website.

Our mission is to improve the health, development and lives of children and young people through excellence in research.

At The Kids, our dedicated team of researchers, clinicians, and students work together with global collaborators to improve the health and wellbeing of children and families affected by some of the most challenging and widespread health issues. Our world-leading researchers have identified early intervention programs for children with developmental delays, found that folic acid in a mother’s diet before and during pregnancy helps prevent neural tube defects, played a pivotal role in the introduction of world-first respiratory syncytial virus immunisation that has saved many lives and prevented hundreds of babies being hospitalised, and identified that a new immunotherapy in combination with standard-of-care chemotherapy improved survival rates for babies with leukaemia.

Learn more on The Kids Research Institute Australia website.

Whether you’re looking to recruit a student or partner with us for research, The University of Western Australia (UWA) can provide access to leading academics and researchers, talented students, advanced equipment and facilities, and innovative technologies. We work with micro, small, medium and large organisations operating locally, nationally and globally to create impact.

UWA administers Perth Biodesign (www.perthbiodesign.au), at the heart of the biomedical innovation ecosystem, offering a portfolio of offerings from 2-day bootcamps to the Biomedical Engineering Capstone and the highly-successful Flagship Program.

UWA also administers Biodesign Australia (www.biodesign.au), networking Biodesign programs across Australia and linking them internationally through the APAC Biodesign Alliance and international biobridges. Its award-winning industry-PhD Research Engagement Program (iPREP) facilitates multidisciplinary teams of PhD students from universities across Australia working on complex industry challenges for up to 3 months, with tangible outcomes.

The Springboard Medical Manufacturing Alliance (www.perthbiodesign.au/springboard) brings together: multiple product designers and manufacturers; SMEs looking to manufacture medical products in Western Australia utilising the experience and expertise of those manufacturers; and The University of Western Australia that is looking to facilitate the ecosystem, collaboratively foster innovation whether internally or externally initiated, and train the workforce of the future. 

Learn more on the UWA website.

TrialsWest is a leading Australian clinical trial site management organisation dedicated to the efficient and high-quality delivery of Phase Ib–IV clinical trials across a wide range of therapeutic areas. Established to meet the growing demand for reliable, patient-focused clinical research in Western Australia, TrialsWest provides end-to-end site management services that uphold the highest standards of clinical and operational excellence.

Our experienced Investigators and Research Coordinators work collaboratively to ensure every trial is conducted with precision, transparency, and in full compliance with Good Clinical Practice (GCP) and all applicable regulatory frameworks.

With a growing network of purpose-built clinics strategically located across Western Australia, TrialsWest combines local expertise with international quality standards.

At the core of our operations is a commitment to participant safety, data accuracy, and continuous improvement. TrialsWest enables its partners to generate dependable clinical evidence that accelerates the development of new treatments and improves health outcomes for patients worldwide.

Through our leadership and collaborative partnerships, TrialsWest plays a pivotal role in bringing world-class clinical research opportunities to Western Australia—strengthening the region’s position as a key contributor to global medical advancement. 

Learn more on the TrialsWest website.

VitalTrace is a clinical-stage medical technology company with the mission to improve fetal and maternal well-being during childbirth, which remains woefully inadequate to this day. DelivAssure, its continuous lactate sensor, is a world-first, revolutionary technology addressing a universal and long-standing problem in childbirth. Current options for fetal monitoring are inaccurate, subjective, and/or impractical, leading to poor health outcomes for mums and babies, but are still used in clinical practice because no better alternatives have been developed for decades.

Learn more on the VitalTrace website

Western Australia has a history of innovative medical research that has been successfully translated and commercialised into novel health and medical therapies and devices.

The WA Life Sciences Innovation Hub is a partnership between MTPConnect (Australia's Life Sciences Innovation Australia for the medical technology, biotechnology, pharmaceutical and digital health sector), The University of Western Australia and the Western Australian Government. The Hub partners drive activities and policies that engage and support all stakeholders across the breadth of the WA health and medical life sciences sector, including researchers, research institutions, the health system, government, investors, service providers, industry, start-ups and clinicians.

The Hub focuses on priority areas such as precision medicine, digital health, regenerative medicine, and clinical trials. By leveraging local capabilities, the Hub aims to position WA as a strategic launch pad for national growth in Australia's MTP sector, leading to substantial job creation and overall economic development in the state.

Learn more on the WALSIH website